[{"orgOrder":0,"company":"Genovis","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene Therapy and Autoimmune Disease","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Licensing Agreement","leadProduct":"Immunoglobulin G Protease","moa":"Neutralizing antibodies","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical","graph3":"Genovis","amount2":0,"therapeuticAreaNew":"Immunology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Genovis \/ Selecta Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Genovis \/ .."}]

Find Clinical Drug Pipeline Developments & Deals by Genovis

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : The partnership leverages Genovis’ proprietary immunoglobulin G protease, IdeXork, and Selecta’s ImmTOR platform to enable the dosing of transformative gene therapies in patients with pre-existing adeno-associated virus immunity and treat IgG-mediate...

                          Brand Name : IdeXork

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 21, 2021

                          Lead Product(s) : Immunoglobulin G Protease

                          Therapeutic Area : Immunology

                          Highest Development Status : Preclinical

                          Sponsor : Selecta Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank